

1 Washington Vaccine Association 2 **Board of Directors Meeting** 3 November 7, 2024; 1:00-4:00 p.m. (PT) 4 5 I. Attendance. This meeting was conducted in-person and virtually. Participating in all or part of the meeting were the following individuals: 6 7 Helms & Company, Inc. 8 Directors 9 John Dunn, MPH, MD, Kaiser Permanente, Chair 29 Patrick Miller, MPH, WVA, Administrative Director 10 Beth Harvey, MD, South Sound Pediatrics, 30 Ashley Ithal, MPH, WVA, Project Director (virtual) 11 Vice Chair (virtual) 31 Lisa White, WVA, Customer and Financial Support 12 Ed Marcuse, MD, MPH, FPIDS, University 32 Specialist (virtual) of Washington, Secretary 33 Leslie Walker, CPA, Mason+Rich, PA (virtual) 13 Chad Murphy, PharmD, Premera 34 15 Steven Caplow, Esq., DWT LLP 35 Others 16 Kara Manley, United Healthcare (virtual) 36 Anne Redman, Esq., Perkins Coie 17 Nicole Saint Clair, MD, Regence 37 Carrie Allen, OneDigital 18 Helen Chea, MD, Molina (virtual) 38 Stacy Parker, OneDigital (virtual) Michele Roberts, MPH, MCHES, Washington 39 Kathryn Kolan, Consultant (virtual) 20 Department of Health 40 Breelyn Young, GSK Jamilia Sherls, DND, MPH, Washington Department 41 Rick Hourigan, MD, Cigna (virtual) 21 of Health 42 Eric Sonju, JD, Washington Office of the Attorney General 23 43 (virtual) 44 Chris Wright, JD, Washington Office of the Attorney WVA 24 Julia Walter Zell, MA., Esq., Executive Director General (virtual) 25 45 Cheri Cagle, Stakeholder Liaison 46 Lisa Templeton, Informed Choice Washington (virtual) 26 47 Bob Runnells, Informed Choice Washington (virtual) 27 48 49 II. Summary of Actions Taken and/or Recommended 50 51 Actions Taken (votes adopted) To approve the minutes of the June 20, 2024, Board Meeting 52 i. 53 ii. Vote to Reappoint Members (Ms. Manley and Dr. Marcuse) 54 iii. Votes to Elect Officers / Committee Chairs for the 2025 calendar year Vote to Ratify Adoption/Publication of 2023-24 Audited Financial Statements 55 iv. 56 Vote to Approve/Publish 2023-24 Annual Report v. 57 III. Minutes 58 59 60 Welcome and Introductions Dr. Dunn called the meeting to order at 1:13 p.m. Ms. Zell provided a notice of recording for the purposes of the 61 meeting minutes. The recording will be deleted once the meeting minutes are approved. Dr. Dunn conducted a roll 62 call, and introductions were given by members, invited guests, and members of the public. 63 64 Consent Calendar 65 66 Dr. Dunn asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously 67 68 VOTED: To approve the minutes of the June 20, 2024, Board Meeting. 69 70 Dr. Dunn asked for a motion to reappoint members. Upon motion duly made and seconded, it was unanimously 71 72 VOTED: To reappoint members whose terms expire in 2024 (Ms. Manley and Dr. Marcuse). 73 74 Dr. Dunn asked for a motion to elect officers and committee chairs. Upon motion duly made and seconded, with proposed officers and chairs abstaining from the vote, it was 75

76



VOTED: To Elect Officers / Committee Chairs as presented on the Board Term Document, with the addition of Steven as an Executive Committee Member.

### IV. Financial Updates

81 82

#### **Current Unaudited Financials**

Mr. Miller reviewed the unaudited financials through September 30, 2024, noting that October financials will be completed next week. He walked the Board through the unaudited financial statements and highlighted that we are running ahead of the administrative budget.

86

# **Investment Policy Statement Update**

- Ms. Zell reviewed the Investment Policy Statement (IPS) revisions approved of by the Finance and Executive
- 89 Committees. She explained the need to add a section on reserves and add detail regarding the processes for projecting,
- 90 retaining, and managing cash reserves.

87 88

### 91 <u>Impact of Respiratory Vaccines on Collections / Vaccine Pipeline</u>

- 92 Mr. Miller provided an overview of a series of items from CY2023 and CY2024 that had the largest impact on
- 93 collections and cash reserves. Ms. Roberts noted that vaccine trends in Washington, and nationally, are negatively
- impacting some vaccine uptake. Ms. Zell and Mr. Miller highlighted plans to rebuild reserves over the next few years.

95 <u>A</u> 96 M

# **Audited Financial Statements**

Ms. Zell reported that WVA received another clean audit from Clifton Larson Allen (CLA). CLA reviewed the results of the audit with the Finance Committee in September, which recommended adoption and publication by the Board.

To Ratify Adoption/Publication of 2023-24 Audited Financial Statements.

Dr. Dunn asked for a motion. Upon motion duly made and seconded, it was unanimously

98 99 100

97

# VOTED:

101 102

# V. ED/AD Updates

103 104

# Legislative Update

Ms. Kolan provided an update on the upcoming political landscape for Washington given the recent election results.

She noted that the newly elected Governor Ferguson announced his executive team today. Ms. Kolan noted that the next six to nine months will require continued relationship building between the WVA and policy makers.

108 109

110

111

### **Hospital Onboarding**

Ms. Zell provided a historical overview of onboarding efforts with birthing hospitals to become DBA compliant in their inpatient and outpatient settings. Thirty of the hospitals are fully onboarded and DBA compliant. Onboarding efforts continue with four (4) others.

112 113 114

## Non-traditional Provider Report

Mr. Miller gave an update on onboarding efforts with non-traditional providers other than hospitals and highlighted 115 116 the funding impacts of those efforts. Ms. Zell provided an overview of current provider type requirements to submit 117 the DBA and the current status of DBA submission by provider type. Ms. Zell proposed policy recommendations to the Board by provider type. She noted that the WVA is currently working with the Department of Health (DOH) and 118 119 the Office of the Insurance Commissioner (OIC) to more clearly define the understanding of the Direct Care Practices 120 (DCP) statutory requirements as well as the impacts of updating WVA's exemption policy related to different provider types. Ms. Sherls added that while a decision is pending regarding DCP participation in the Childhood Vaccine 121 Program (VCP), no new DCP providers will be enrolled until statutory determination is made. 122

123 124

125

Ms. Zell reported that joint efforts between the DOH and WVA have been successful in finding a solution for onboarding providers. The DOH has committed to not shipping vaccines prior to a provider demonstrating the ability to submit a DBA.

126 127

Mr. Miller reviewed the next steps for onboarding Local Health Jurisdictions (LHJs), remaining mobile providers, and remaining School Based Health Clinics (SBHCs). Ms. Sherls added that options for onboarding LHJs and SBHCs were raised during joint summer 2024 workgroup meetings. Dr. Marcuse requested we consider volume data by





provider type to accommodate vulnerable populations and "vaccine deserts." The policy recommendations will be 131 132 reviewed again during the February board meeting. 133 **Annual Report** 134 135 Ms. Zell reviewed the 2023-2024 Annual Report. She noted that the Annual Report is distributed to policy makers, partners, and is posted to the WVA website. Dr. Dunn asked for a motion to approve/publish 2023-24 Annual Report 136 as presented. 137 138 Upon motion duly made and seconded, it was unanimously 139 140 **VOTED:** To Approve/Publish 2023-24 Annual Report as presented. 141 142 143 VI. Vaccine Committee Update 144 145 Dr. Marcuse provided a historical overview of the Vaccine Committee including the original intent for its creation. 146 147 He noted that due to changes over time that the scope of activities for the Vaccine Committee has increased and has 148 resulted in the need to review and revise the WVA Vaccine Committee Charter. 149 VII. Public Comments - None. 150 151 VIII. Executive Session - Confidential. 152 153 IX. Closing 154

Dr. Dunn reviewed the FY2025 WVA Meeting Schedule.

155

156